Veledimex-INXN-1001-DataSheet-MedChemExpress_第1頁
Veledimex-INXN-1001-DataSheet-MedChemExpress_第2頁
Veledimex-INXN-1001-DataSheet-MedChemExpress_第3頁
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)

文檔簡介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEVeledimexCat. No.: HY-16785CAS No.: 1093130-72-3Synonyms: INXN-1001; RG-115932分式: CHNO分量: 438.6作靶點: Interleukin Related; Cytochrome P450作通路: Immunology/Inflammation; Metabolic Enzyme/Protease儲存式: Powder -20C 3 years4C 2 yearsIn

2、solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實驗 DMSO : 25 mg/mL (57.00 mM; Need ultrasonic)H2O : 90% corn oilSolubility: 2.5 mg/mL (5.70 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIOLOGICAL ACTIVITY物活性 Veledimex種專有基因治療啟動系統(tǒng)的激活劑配體,也是CYP3A4/5的溫和抑制劑配體。體內(nèi)研究 Veledimex generally has mo

3、derate to low oral bioavailability after a single oral administration in mice andmonkeys (-56% in mice and up to 17.4% in cynomolgus monkeys) with mostly low plasma clearance (1399and 1170 mL/h per kilogram in mice and monkeys, respectively), high volume of distribution (20271 and 9180mL/h per kilog

4、ram in mice and monkeys, respectively), and long terminal half-lives (-10 hours in mice and -30hours in monkeys) after intravenous administration 1. Ad-RTS-mIL-12 + veledimex have demonstrated adose-related increase in tumor IL-12 mRNA and IL-12 protein expression. Discontinuation of veledimexresult

5、ed in a return to baseline IL-12 mRNA and protein expression in numerous syngeneic mouse tumormodels. Veledimex crosses the blood-brain-barrier in both naive and orthotopic GL-261 mice with increasedbrain tissue level of -6 fold observed in tumor bearing vs. normal mice. Ad-RTS-mIL-12 + veledimexdem

6、onstrate a dose-related increase in survival without significant adverse events 2.REFERENCES1. Cai H, et al. Plasma Pharmacokinetics of Veledimex, a Small-Molecule Activator Ligand for a Proprietary Gene Therapy PromoterSystem, in Healthy Subjects. Clin Pharmacol Drug Dev. 2017 May;6(3):246-257.2. John A. Barrett, INTRATUMORAL REGULATED EXPRESSION OF IL-12 AS A GENE THERAPY APPROACH TO TREATMENT OFGLIOMA. Neuro Oncol. 2015 Nov; 17(Suppl 5): v113.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

最新文檔

評論

0/150

提交評論